The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 11, 2021 18:20 ET | Source: Prelude Therapeutics, Inc. Prelude Therapeutics, Inc. Wilmington, Delaware, UNITED STATES
WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering
End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region
This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best-laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C., and Maryland.
The regional life science ecosystem was prepared and pivoted rapidly to not only ensure continued operations, but also to redirect resources, talent and technologies to creating testing, developing COVID-19 therapies and progressing SARS-CoV-2 vaccine candidates.
Is CORT A Good Stock To Buy According To Hedge Funds? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
60 Stocks Moving In Thursday s Mid-Day Session Benzinga 12/10/2020
Gainers
Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 clinical trial of Immutep s eftilagimod alpha in up to 152 metastatic breast cancer patients in China. Immutep said the study follows encouraging data reported by it in its APIAC Phase 2b study announced at the end of March and presented at the SABCS.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) shares surged 67.4% to $95.60. Greenwich LifeSciences shares jumped 998% on Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.